Targeting Cancer with CT47A9 (G728042)

Target Name: CT47A9

NCBI ID: G728042

CT47A9

Targeting Cancer with CT47A9

Cancer/testis antigen 47 (CT47A9) is a protein that is expressed in a variety of tissues throughout the body, including the lungs, liver, and nervous system. It is also highly expressed in many types of cancer, including breast, ovarian, and prostate cancer. This makes it an attractive target for cancer researchers because it is often overexpressed in cancer cells and can be used as a biomarker for these cancers.

One of the main advantages of CT47A9 is its ability to be targeted by small molecules. This is because the protein has a large, positively charged surface that is trapped by small molecules, making it a stable target. This is in contrast to many other proteins, which have a more diffuse or negative charge and are harder to target.

Another advantage of CT47A9 is its expression in a variety of tissues, which makes it a potential biomarker for many different types of cancer. This makes it a useful tool for studying the effects of different treatments on cancer cells in different organs and tissues.

In addition to its potential as a biomarker, CT47A9 is also a potential drug target. Many studies have suggested that CT47A9 may be involved in the development and progression of cancer, and that targeting this protein may be a useful way to treat cancer.

One way that researchers are exploring CT47A9 as a drug target is by using small molecules to inhibit its activity. These small molecules can be either agonists (which enhance the activity of CT47A9) or antagonists (which reduce its activity). By using these small molecules, researchers can study how different treatments affect CT47A9 expression and activity.

Another approach that researchers are using to target CT47A9 is by using antibodies to block its function. These antibodies can be used to tag CT47A9 with a payload of radioactive or fluorescent tags, which can be used to track the protein's location and activity. This can be a useful way to study how CT47A9 interacts with other molecules in the body.

While there is still much to be learned about CT47A9 and its role in cancer, its potential as a drug target and biomarker is an exciting area of research. As more studies are done to understand how CT47A9 interacts with cancer cells, researchers may be able to develop new treatments for this deadly disease.

Protein Name: Cancer/testis Antigen Family 47 Member A9

The "CT47A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets